| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_97e97b4301eb34468ad145e7df46b2af
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_67e1aad9cf209e2ac4d9b2789e5d27e4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dbe6a152ab369ec0c2c593941a1ee036 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1694
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1617
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1611 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0075
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0078
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0073
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-16 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7048 |
| filingDate |
2003-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_61d512e1e80a8df821d11f078174eb78
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1af6e3f23daaead144bceeafbdab2f17 |
| publicationDate |
2004-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2004060351-A3 |
| titleOfInvention |
Pharmaceutical formulation with an insoluble active agent for pulmonary administration |
| abstract |
A pharmaceutical formulation for pulmonary administration comprises particulates comprising an active agent particle in a lipid matrix, the active agent having a solubility in water of less than 1.0 mg/ml. In one version, at least 90% of the active agent particles in the pharmaceutical formulation have a geometric diameter less than 3 µm. In another version, the insoluble active agent comprises amphotericin B. The particulates may have a size and shape to allow the aerosolized pharmaceutical formulation to be delivered to the deep lung. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9205345-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9248584-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9084944-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9084976-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9358478-B2 |
| priorityDate |
2002-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |